Sep. 6 at 6:58 AM
$ATNM ⭐ Clean Synthesis — Novartis’s RTOR Urgency
Based on the sourced safety events:
**Novartis now has a regulatory and clinical imperative to adopt a safer conditioning agent.
I‑131–apamistamab (Iomab‑ACT) is uniquely suited for RTOR because it reduces inflammatory toxicity, provides predictable lymphodepletion, and has FDA familiarity.
The IEC‑HS deaths materially increase Novartis’s urgency to secure this platform before RTOR begins.**
If you want, I can now produce:
✔ A buyer‑specific RTOR timing model (Novartis vs J&J vs BMS vs AZ vs Merck)
✔ A board‑ready “RTOR Value Inflection” slide
✔ A full M&A timing deck integrating RTOR, Herthena, and Seth’s Form 4
